CXCR4 and gastric cancer: As showed in Fig 4B (S5 Table), CXCR12 significantly abrogated the inhibitory effect of regorafenib, and CXCL12 together with CXCR4 overexpression further attenuated the inhibition of regorafenib in gastric cancer cell invasion.